GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

Vaccines help your body learn to fight infections. Arexvy contains proteins from the RSV virus. These virus proteins will not make you sick or give you RSV. When these virus proteins come in ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...

The EMA’s acceptance of the application to extend the use of Arexvy represents a significant step in broadening the vaccine’s reach to a wider adult population. Arexvy was the first RSV ...

Arexvy is a vaccine used to prevent certain lower respiratory infections caused by respiratory syncytial virus (RSV). Arexvy’s cost may depend on factors such as whether you have health ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...